Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Respir Res

ICON Health Economics, ICON, Toronto, ON, Canada.

Published: January 2019

Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348614	PMC
http://dx.doi.org/10.1186/s12931-019-0985-2	DOI Listing

Publication Analysis

correction cost-effectiveness

cost-effectiveness analysis

analysis umeclidinium

umeclidinium bromide/vilanterol

bromide/vilanterol 625/25

625/25 mcg

mcg versus

versus tiotropium/olodaterol

tiotropium/olodaterol 5/5

5/5 mcg

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!